Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (117)

2024

  1. A multitrait genetic study of hemostatic factors and hemorrhagic transformation after stroke treatment

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 4, pp. 936-950

  2. Anticoagulation Use and Endovascular Thrombectomy in Patients with Large Core Stroke: A Secondary Analysis of the SELECT2 Trial

    Annals of Neurology

  3. Clinical relevance of intracranial hemorrhage after thrombectomy versus medical management for large core infarct: a secondary analysis of the SELECT2 randomized trial

    Journal of NeuroInterventional Surgery, pp. 1-8

  4. Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients with Large Ischemic Strokes: A Prespecified Analysis of the SELECT2 Trial

    JAMA Neurology, Vol. 81, Núm. 4, pp. 327-335

  5. Endovascular Thrombectomy for Large Ischemic Stroke Across Ischemic Injury and Penumbra Profiles

    JAMA, Vol. 331, Núm. 9, pp. 750-763

  6. Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial

    The Lancet, Vol. 403, Núm. 10428, pp. 731-740

  7. Penumbral Rescue by normobaric O = O administration in patients with ischemic stroke and target mismatch proFile (PROOF): Study protocol of a phase IIb trial

    International Journal of Stroke, Vol. 19, Núm. 1, pp. 120-126

  8. SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population

    Database : the journal of biological databases and curation, Vol. 2024

  9. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial

    The Lancet Neurology, Vol. 23, Núm. 8, pp. 775-786

  10. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial

    The Lancet, Vol. 403, Núm. 10444, pp. 2597-2605

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  3. Intensive 90-day textile wearable Holter monitoring: an alternative to detect paroxysmal atrial fibrillation in selected patients with cryptogenic stroke

    Heart and Vessels, Vol. 38, Núm. 1, pp. 114-121

  4. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

  5. Trial of Endovascular Thrombectomy for Large Ischemic Strokes.

    New England Journal of Medicine, Vol. 388, Núm. 14, pp. 1259-1271

2022

  1. A Polygenic Risk Score Based on a Cardioembolic Stroke Multitrait Analysis Improves a Clinical Prediction Model for This Stroke Subtype

    Frontiers in Cardiovascular Medicine, Vol. 9

  2. A first update on mapping the human genetic architecture of COVID-19

    Nature

  3. Blood-Based Biomarkers to Search for Atrial Fibrillation in High-Risk Asymptomatic Individuals and Cryptogenic Stroke Patients

    Frontiers in Cardiovascular Medicine, Vol. 9

  4. Multi-Ancestry GWAS reveals excitotoxicity associated with outcome after ischaemic stroke

    Brain, Vol. 145, Núm. 7, pp. 2394-2406

  5. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806